安徽丰原药业股份有限公司关于回购注销部分限制性股票完成暨股本变动的公告

Core Viewpoint - Anhui Fengyuan Pharmaceutical Co., Ltd. has completed the repurchase and cancellation of a portion of restricted stocks, resulting in a decrease in total share capital by 88,200 shares, which is 0.0190% of the total share capital before the repurchase [2][11]. Group 1: Repurchase and Cancellation Details - The repurchase involved 3 incentive targets, with a total of 88,200 shares being repurchased at a price of 2.67 yuan per share, amounting to a total payment of 246,091.23 yuan [2][10]. - The repurchase was completed on January 9, 2026, reducing the company's total share capital from 464,773,722 shares to 464,685,522 shares [2][11]. Group 2: Background of the Stock Incentive Plan - The stock incentive plan was approved during the board meeting on August 12, 2022, with independent directors providing opinions on its benefits for the company's sustainable development [3]. - The plan included a public announcement of the incentive targets from August 15 to August 24, 2022, with no objections received [4]. - The first grant of restricted stocks was approved on September 23, 2022, with 19,970,000 shares granted at a price of 4.13 yuan per share [5]. Group 3: Reasons for Repurchase - The repurchase was necessitated by one incentive target leaving the company and two others failing to meet performance criteria, leading to the cancellation of 33,600 shares and 54,600 shares, respectively [9].